Global Journal of Surgery
ISSN (Print): 2379-8742 ISSN (Online): 2379-8750 Website: http://www.sciepub.com/journal/js Editor-in-chief: Baki Topal
Open Access
Journal Browser
Go
Global Journal of Surgery. 2020, 8(2), 24-28
DOI: 10.12691/js-8-2-1
Open AccessCase Report

Inflammatory Myofibroblastic Pancreas Tumor: A Case Report

Youssef Jakhlal1, , Fouad Zouaidia2 and Abdellatif Settaf1

1Department of Digestive Surgery B, Ibn Sina Teaching Hospital, Mohammed V University, Rabat, Morocco

2Department of Anatomopathology, Ibn Sina Teaching Hospital, Mohammed V University, Rabat, Morocco

Pub. Date: August 03, 2020

Cite this paper:
Youssef Jakhlal, Fouad Zouaidia and Abdellatif Settaf. Inflammatory Myofibroblastic Pancreas Tumor: A Case Report. Global Journal of Surgery. 2020; 8(2):24-28. doi: 10.12691/js-8-2-1

Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare tumor; characterized by a proliferation of myofibroblasts associated with inflammatory reaction cells and which can be observed at the various anatomical sites. The pancreas represents a very rare localization of this tumor. Surgery is the standard treatment, but for inoperable tumors; there is no consensus. We report a case of an inextirpable pancreatic IMT in a 46-years-old woman and we also carry out a literature review.

Keywords:
inflammatory myofibroblastic tumor pancreas ALK

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CDM, Unni KK, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon : IARC Press; 2002. p. 91-3.
 
[2]  Sastre-Garau X, Couturier J, Derré J, et al. Inflammatory myofibroblastic tumour (inflammatory pseudotumour) of the breast. Clinicopathological and genetic analysis of a case with evidence for clonality. J Pathol. 2002; 196:97-102.
 
[3]  World Health Organization. World Health Organization classification of tumours of the breast. 4th ed. Lyon: IARC Press; 2012. p. 133.
 
[4]  Yamamoto, H., K. Watanabe, M. Nagata, K. Tasaki, I. Honda, and S. Watanabe. 2002. Inflammatory myofibroblastic tumor (IMT) of the pancreas. J. Hepatobiliary Pancreat. Surg. 9:116-119.
 
[5]  Fletcher CDM, Bridge JA, Hogendoorn P and Mertens F (eds): World Health Organization Classification of Tumours of Soft Tissue and Bone. In: World Health Organization Classification of Tumors. Vol 5. 4th edition. IARC Press, Lyon, 2013.
 
[6]  Fragoso AC, Eloy C, Estevão‑Costa J, Campos M, Farinha N and Lopes JM: Abdominal inflammatory myofibroblastic tumor a clinicopathologic study with reappraisal of biologic behavior. J Pediatr Surg 46: 2076‑2082, 2011.
 
[7]  Coindre JM: New WHO classification of tumours of soft tissue and bone. Ann Pathol 32 (Suppl 5): S115‑S116, 2012 (In French).
 
[8]  Hiroyuki Matsubayashi, Katsuhiko Uesaka, Keiko Sasaki, Seitaro Shimada and al: A Pancreatic Inflammatory Myofibroblastic Tumor with Spontaneous Remission: A Case Report with a Literature Review. Diagnostics 2019, 9, 150.
 
[9]  Sim A, Lee MW and Nguyen GK: Inflammatory myofibroblastic tumour of the pancreas. Can J Surg 51, E23-E24, 2008.
 
[10]  Dagash H, Koh C, Cohen M, Sprigg A and Walker J: Inflammatory myofibroblastic tumor of the pancreas: A case report of 2 pediatric cases ‑ steroids or surgery? J Pediatr Surg 44: 1839-1841, 2009.
 
[11]  Matsubayashi, H.; Matsui, T.; Yabuuchi, Y.; Imai, K.; Tanaka, M.; Kakushima, N.; Sasaki, K.; Ono, H. Endoscopic ultrasonography guided-fine needle aspiration for the diagnosis of solid pancreaticobiliary lesions: Clinical aspects to improve the diagnosis. World J. Gastroenterol. 2016, 22, 628-640.
 
[12]  Ishiwatari, H.; Sato, J.; Fujie, S.; Sasaki, K.; Kaneko, J.; Satoh, T.; Matsubayashi, H.; Kishida, Y.; Yoshida, M.; Ito, S.; et al. Gross visual inspection by endosonographers during endoscopic ultrasound-guided fine needle aspiration. Pancreatology 2019, 19, 191-195.
 
[13]  Fujie, S.; Ishiwatari, H.; Sasaki, K.; Sato, J.; Matsubayashi, H.; Yoshida, M.; Ito, S.; Kawata, N.; Imai, K.; Kakushima, N.; et al. Comparison of the Diagnostic Yield of the Standard 22-Gauge Needle and the New 20-Gauge Forward-Bevel Core Biopsy Needle for Endoscopic Ultrasound-Guided Tissue Acquisition from Pancreatic Lesions. Gut Liver 2019, 13, 349-355.
 
[14]  Sato, J.; Ishiwatari, H.; Sasaki, K.; Fujie, S.; Kaneko, J.; Satoh, T.; Matsubayashi, H.; Kishida, Y.; Yoshida, M.; Ito, S.; et al. Benefit of high negative pressure during endoscopic ultrasound-guided fine-needle aspiration with standard 22-gauge needles for pancreatic lesions: A retrospective comparative study. Scand. J. Gastroenterol. 2019, 54, 108-113.
 
[15]  Hussong, J.W.; Brown, M.; Perkins, S.L.; Dehner, L.P.; Con, C.M. Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod. Pathol. 1999, 12, 279-286.
 
[16]  Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001; 14:569-576.
 
[17]  Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, Asaka R, Okumura S, Nakagawa K, Mano H, Ishikawa Y. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: Reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Rese 2011; 17: 3341-3348.
 
[18]  Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 354-362.
 
[19]  Coffin, C.M.; Hornick, J.L.; Fletcher, C.D. Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 2007, 31, 509-520.
 
[20]  Przkora, R.; Bolder, U.; Schwarz, S.; Jauch, K.W.; Spes, J.; Andreesen, R.; Mackensen, A. Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs. Eur. J. Clin. Investig. 2004, 34, 320-321.
 
[21]  Habib, L.; Son, J.H.; Petris, C.; Kazim, M. Spontaneous regression of inflammatory myofibroblastic tumor of the orbit: A case report and review of literature. Orbit 2017, 36, 178-182.
 
[22]  Tomazic A, Gvardijancic D, Maucec J and Homan M: Inflammatory myofibroblastic tumor of the pancreatic head ‑ a case report of a 6 months old child and review of the literature. Radiol Oncol 49: 265-270, 2015.
 
[23]  Pungpapong S, Geiger XJ and Raimondo M: Inflam matory myofibroblastic tumor presenting as a pancreatic mass: A case report and review of the literature. JOP 5: 360-367, 2004.
 
[24]  Misato Ogata, Yukimasa Hatachi, Takatsugu Ogata, Hironaga Satake: Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation: A Case Report. Intern Med Advance Publication.
 
[25]  Masafumi Saiki, Fumiyoshi Ohyanagi, Ryo Ariyasu, Junji Koyama and al: Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Japanese Journal of Clinical Oncology, 2017, 47(12). 1189-1192.
 
[26]  Kube S, Vokuhl C, Dantonello T, et al. Inflammatory myofibroblastic tumors-a retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2018; e27012.
 
[27]  Maruyama et al: Chemotherapy for inflammatory myofibroblastic tumor. Molecular and clinical oncology. 7: 521-524, 2017.
 
[28]  Ameet Patel, Mehmet H. Kocoglu, Akash Kaul: Therapeutic strategies for durable response in plasma cell granulomas in the central nervous system. Annals of Hematology.
 
[29]  Cottrell TR, Duong AT, Gocke CD, Xu H, Ogurtsova A, Taube JM, Belchis DA (2018) PD-L1 expression in inflammatory myofibroblastic tumors. Mod Pathol 31:1155-1163.
 
[30]  Gleason BC, Hornick JL (2008) Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 61(4): 428-437.
 
[31]  Garcia BA, Tinsley S, Schellenberger T, Bobustuc GC (2012) Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab. Med Oncol 29(4): 2452-2455.